Industry Symposium with ACPE Credit and Lunch
Addressing Persistent Myths and Misconceptions in Tardive Dyskinesia
Supported by Neurocrine and Teva

The presentation will begin after in-person meals are served (an estimated 15-30 minute delay). Thank you for your patience.

Tardive dyskinesia (TD), a heterogenous and generally persistent disorder of involuntary hyperkinetic movements of the body and face, is a common potential side effect of treatment with antipsychotic medications. Affecting over 500,000 people in the United States, TD significantly diminishes quality of life, impacting all aspects of patients’ lives and contributing to high rates of nonadherence to antipsychotic therapy and suboptimal outcomes. Although recognition, assessment, and management of TD have improved since the 2017 FDA approval of two novel vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD, a variety of myths and misconceptions regarding this condition and its optimal management persist. This session will address these common myths and misconceptions in order to improve TD management and positively impact patient outcomes. 

 

Claiming Credit

To be eligible for credit, participants must complete the activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

For questions regarding this educational activity, please call 609-371-1137 or email accreditation@hmpglobal.com.

Educational grants from Neurocrine Biosciences and Teva Pharmaceuticals